---
title: "Shanghai Fosun Pharmaceutical Files HKEX Return Disclosing Share Buyback"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305947957.md"
description: "Shanghai Fosun Pharmaceutical filed with the HKEX on November 18, 2026, disclosing a share buyback. The company repurchased 1,807,000 H shares for HKD 26.94 million at prices ranging from HKD 14.6 to 15.1 per share. All repurchased shares will be held as treasury shares."
datetime: "2026-11-18T09:30:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305947957.md)
  - [en](https://longbridge.com/en/news/305947957.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305947957.md)
generator: "portal-rs"
---

# Shanghai Fosun Pharmaceutical Files HKEX Return Disclosing Share Buyback

-   Fosun Pharma repurchased 1,807,000 H shares on November 18, 2026, for HKD 26.94 million. \* Repurchase prices ranged from HKD 14.6 to HKD 15.1 per share; all repurchased shares will be held as treasury shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261118-12417110), on November 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [02196.HK](https://longbridge.com/en/quote/02196.HK.md)
- [600196.CN](https://longbridge.com/en/quote/600196.CN.md)

## Related News & Research

- [Shanghai Fosun Pharma Files HKEX Next-Day Return Disclosing Share Buyback](https://longbridge.com/en/news/306090882.md)
- [Shanghai Fosun Pharmaceutical Files Next-Day HKEX Return Announcing Share Buyback](https://longbridge.com/en/news/305444728.md)
- [Fosun Pharma Starts Phase II Trial of FXR0906 for Hypertriglyceridemia in China](https://longbridge.com/en/news/305650774.md)
- [Fosun Subsidiary Receives Clinical-Trial Approval for FAP PET Drug](https://longbridge.com/en/news/305658233.md)
- [Fosun Pharma Subsidiary Fosun Kairos Starts Phase II Trial of FKC516 for B-Cell Lymphoma](https://longbridge.com/en/news/305300840.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**